For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
-- New weight loss drugs like Ozempic, Wegovy and Zepbound
may make oral birth control pills less effective at certain points --
Eli Lilly's Mounjaro and Zepbound, which contain the same compound, clearly instruct prescribers to "advise females using oral contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation."3 Patients are cautioned that "birth control pills may not work as well," and that their "healthcare provider may recommend another type of birth control…"4
"The use of GLP-1 agonists to help women lose weight has become more prevalent," noted
Users of oral birth control considering GLP-1 treatment are encouraged to plan ahead to prevent unintended pregnancy. Having a contraceptive strategy in place and the right product at your fingertips enables spontaneous intimacy no matter where you are in your GLP-1 dosing schedule.
An on-demand, hormone-free method is a logical choice to provide these patients additional protection they need. One such option, Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, puts the power in her hands and with an FDA-approved contraceptive that she uses only when she needs it.
The company behind Phexxi, women's health innovator
About
Phexxi® is a registered trademark of
Sources
1 Trilliant Health report
2 Reuters 'Lilly CEO says weight-loss drug Zepbound weekly prescriptions hit 25,000 in December.'
3 Zepbound Prescribing Information. https://uspl.lilly.com/zepbound/zepbound.html#pi
4 Zepbound Safety Summary with Warnings. https://zepbound.lilly.com/
Forward-Looking Statements
This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, including, without limitation, the anticipated benefits of the contemplated
Media Contact
media@evofem.com
Investor Contact
araskopf@evofem.com
Mobile: (917) 673-5775
View original content to download multimedia:https://www.prnewswire.com/news-releases/for-women-using-glp-1-receptor-agonists-who-take-oral-birth-control-pills-hormone-free-phexxi-contraceptive-gel-is-a-logical-solution-to-help-prevent-unintended-pregnancy-302082439.html
SOURCE